Use of hepcidin as a regulator of iron homeostasis
US-9782453-B2 · Oct 10, 2017 · US
Use of hepcidin as a regulator of iron homeostasis
US10004784B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10004784-B2 |
| Application number | US-201715672616-A |
| Country | US |
| Kind code | B2 |
| Filing date | Aug 9, 2017 |
| Priority date | May 25, 2001 |
| Publication date | Jun 26, 2018 |
| Grant date | Jun 26, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention concerns the use of hepcidin for the diagnosis and therapy of disorders of iron homeostasis. Hepcidin can be used in the treatment of disorders resulting from iron overload while inhibitors of hepcidin can be used in the treatment of anaemia.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method for treating hereditary hemochromatosis in a patient in need thereof, comprising administering to the patient a polypeptide comprising a sequence of SEQ ID NO: 1. 2. A method according to claim 1 , wherein the polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 2. 3. A method according to claim 1 , wherein the polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 3. 4. A method according to claim 1 , wherein the polypeptide consists of the amino acid sequence set forth in SEQ ID NO: 3. 5. A method according to claim 1 , wherein the polypeptide is administered parenterally. 6. A method according to claim 5 , wherein the polypeptide is administered by intramuscular, subcutaneous, intravenous, or intraperitoneal injection. 7. A method according to claim 4 , wherein the polypeptide is administered parenterally. 8. A method according to claim 7 , wherein the polypeptide is administered by intramuscular, subcutaneous, intravenous, or intraperitoneal injection. 9. A method for treating anemia in a patient in need thereof, comprising administering to the patient a polypeptide comprising a sequence of SEQ ID NO: 1. 10. A method according to claim 9 , wherein the polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 2. 11. A method according to claim 9 , wherein the polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 3. 12. A method according to claim 9 , wherein the polypeptide consists of the amino acid sequence set forth in SEQ ID NO: 3. 13. A method according to claim 9 , wherein the polypeptide is administered parenterally. 14. A method according to claim 13 , wherein the polypeptide is administered by intramuscular, subcutaneous, intravenous, or intraperitoneal injection. 15. A method according to claim 12 , wherein the polypeptide is administered parenterally. 16. A method according to claim 15 , wherein the polypeptide is administered by intramuscular, subcutaneous, intravenous, or intraperitoneal injection. 17. A method for treating thalassemia in a patient in need thereof, comprising administering to the patient a polypeptide comprising a sequence of SEQ ID NO: 2. 18. A method according to claim 17 , wherein the polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 3. 19. A method according to claim 17 , wherein the polypeptide consists of the amino acid sequence set forth in SEQ ID NO: 3. 20. A method according to claim 17 , wherein the polypeptide is administered parenterally. 21. A method according to claim 20 , wherein the polypeptide is administered by intramuscular, subcutaneous, intravenous, or intraperitoneal injection. 22. A method according to claim 19 , wherein the polypeptide is administered parenterally. 23. A method according to claim 22 , wherein the polypeptide is administered by intramuscular, subcutaneous, intravenous, or intraperitoneal injection.
Assignees
Inventors
Classifications
Drugs for disorders of the cardiovascular system · CPC title
Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure · CPC title
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Antianaemics · CPC title
Antineoplastic agents · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10004784B2 cover?
- The invention concerns the use of hepcidin for the diagnosis and therapy of disorders of iron homeostasis. Hepcidin can be used in the treatment of disorders resulting from iron overload while inhibitors of hepcidin can be used in the treatment of anaemia.
- Who is the assignee on this patent?
- Inst Nat Sante Rech Med
- What technology area does this patent fall under?
- Primary CPC classification A61K38/22. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jun 26 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).